北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia
作者: Kush, Debra1; Kim, Hyo-Soo1,2; Hu, Da Yi3; Liu, Ji1; Sirah, Waheeda1; Sapre, Aditi1; Sisk, Christine McCrary1; Paolini, John F.1; Maccubbin, Darbie
关键词: Extended-release niacin ; Flushing ; Laropiprant ; Primary hypercholesterolemia ; Mixed hyperlipidemia
刊名: JOURNAL OF CLINICAL LIPIDOLOGY
发表日期: 2009-06-01
DOI: 10.1016/j.jacl.2009.04.048
卷: 3, 期:3, 页:179-186
收录类别: SCI ; ISTP
文章类型: Proceedings Paper
WOS标题词: Science & Technology
类目[WOS]: Pharmacology & Pharmacy
研究领域[WOS]: Pharmacology & Pharmacy
关键词[WOS]: NICOTINIC-ACID ; NIACIN ; DYSLIPIDEMIA ; TRIAL ; TOLERABILITY ; CHOLESTEROL ; PREVENTION ; DISEASE ; SAFETY
英文摘要:

BACKGROUND: Niacin has proven lipid-modifying efficacy and cardiovascular benefit; however, it is underused because of skin flushing, a process mediated primarily by prostaglandin D(2) (PGD(2)). Laropiprant (LRPT), a PGD(2) receptor (DPI) antagonist that mitigates niacin-induced flushing, has been combined with extended-release niacin (ERN) into a fixed-dose tablet containing I of ERN and 20 mg of LRPT (ERN/LRPT 1 g). In a large-scale (n = similar to 1600), multinational, 6-month study in dyslipidemic patients, ERN/LRPT 2 g produced superior lipid-modifying efficacy vs placebo, whether administered alone or with concomitant statins.

OBJECTIVE: This Phase III, randomized, double-blind study evaluated the lipid-modifying efficacy of ERN/LRPT alone or added to ongoing statins in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia.

METHODS: After a 4-week placebo run-in, patients were randomized to ERN/LRPT I g (n = 322) or placebo (PBO; n = 324). After 4 weeks, the dose was advanced to 2 tablets/d (ERN/LRPT 2 g or PBO) for 8 additional weeks. End points included effects of ERN/LRPT 2 g vs P130 on low-density lipoprotein cholesterol (LDL-C; primary), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), and other lipids/lipoproteins.

RESULTS: Relative to P130, ERN/LRPT 2 g produced significant (P<.001) changes in LDL-C 14.7%), HDL-C (15.9%), TG (-23.4%), LDL-C:HDL-C (-25.5%), non-HDL-C (-16.4%), apolipoprotein (Apo) B (-15.4%), and Apo A-I (5.3%) from baseline to week 12 in the total population. Similar results were observed in patients treated with ERN/LRPT alone or added to ongoing statin.

CONCLUSION: ERN/LRPT 2 g, administered alone or with a statin, produced significant improvements in multiple lipid/lipoprotein parameters in dyslipidemic Asian patients. (C) 2009 National Lipid Association. All rights reserved.

语种: 英语
WOS记录号: WOS:000267614700005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65175
Appears in Collections:北京大学第二临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Merck Res Labs, Rahway, NJ 07065 USA
2.Seoul Natl Univ Hosp, Seoul 110744, South Korea
3.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China

Recommended Citation:
Kush, Debra,Kim, Hyo-Soo,Hu, Da Yi,et al. Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia[J]. JOURNAL OF CLINICAL LIPIDOLOGY,2009,3(3):179-186.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Kush, Debra]'s Articles
[Kim, Hyo-Soo]'s Articles
[Hu, Da Yi]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Kush, Debra]‘s Articles
[Kim, Hyo-Soo]‘s Articles
[Hu, Da Yi]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace